Skip to main content

Table 3 Univariate and multivariate analysis of overall survival from the start of first-line chemotherapy

From: Combination versus single-agent as palliative chemotherapy for gastric cancer

Prognostic FactorsBefore propensity score matchingAfter propensity score matching
UnivariateMultivariateUnivariateMultivariate
MS
(months)
P valueaHR95% CIP valuebMS (months)P valueaHR95% CIP valueb
Gender 0.728    0.688   
 Male10    9    
 Female10    8    
Age (years) 0.012    0.565   
  < 7011 1  9    
  ≥ 708 1.010.80–1.270.9419    
PS (ECOG) < 0.0001    < 0.0001   
 0, 111 11 10 11 
  ≥ 25 1.471.13–1.920.0045 1.591.10–2.280.013
Disease status 0.315    0.336   
 Primary metastatic10    8    
 Recurrent10    10    
Tumor differentiation 0.022    0.215   
 Well, moderate12 1  11    
 Poor10 1.321.06–1.650.0159    
 Signet ring cell8 1.641.30–2.07< 0.00017    
 Combined, others11 1.210.96–1.530.10212    
Peritoneal metastasis 0.001    0.037   
 No11 1  10 1  
 Yes9 1.191.01–1.400.0407 1.250.96–1.640.099
Liver metastasis 0.595    0.613   
 No11    9    
 Yes9    9    
Palliative resection < 0.0001    < 0.0001   
 No9 1  8 1  
 Yes19 0.420.34–0.52< 0.000115 0.590.41–0.850.005
1st line CTx < 0.0001    0.322   
 Single-agent8 1  8    
 Combination11 0.820.66–1.020.06910    
CTx lines < 0.0001    < 0.0001   
 1st line CTx6 1  6 1  
  ≥ 2nd line CTx14 0.690.59–0.82< 0.000113 0.590.45–0.77< 0.0001
NLR < 0.0001    0.013   
 Low13 1  10 1  
 High8 1.351.14–1.610.0017 1.250.95–1.650.111
PLR < 0.0001    0.539   
 Low12 1  9    
 High9 1.211.02–1.440.0338    
  1. a Log-rank test, bCox proportional-hazards regression model
  2. MS median survival, HR hazard ratio, PS performance status, ECOG Eastern Cooperative Oncology Group, CTx chemotherapy, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio